Review article · 2016 · Open access

Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview

Peter M. Fischer

Medicinal Research Reviews, 37(2), 314–367 · Published 24 October 2016 · DOI 10.1002/med.21409

Open PDFView at the publisherCite this paper

In brief

“Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview” is a 2016 review article by Peter M. Fischer, published in Medicinal Research Reviews. OpenAlex counts 84 citations as of 19 November 2026. It is open access under a CC BY licence: the full text is free to read at Repository@Nottingham (University of Nottingham).

Citations
84
Most cited in
2021 (16)
Field-weighted impact
1.00
References
412
Authors
1

Abstract

Kinase inhibitor research is a comparatively recent branch of medicinal chemistry and pharmacology and the first small-molecule kinase inhibitor, imatinib, was approved for clinical use only 15 years ago. Since then, 33 more kinase inhibitor drugs have received regulatory approval for the treatment of a variety of cancers and the volume of reports on the discovery and development of kinase inhibitors has increased to an extent where it is now difficult-even for those working in the field-easily to keep an overview of the compounds that are being developed, as currently there are 231 such compounds, targeting 38 different protein and lipid kinases (not counting isoforms), in clinical use or under clinical investigation. The purpose of this review is thus to provide an overview of the biomedical rationales for the kinases being targeted on the one hand, and the design principles, as well as chemical, pharmacological, pharmaceutical, and toxicological kinase inhibitor properties, on the other hand. Two issues that are especially important in kinase inhibitor research, target selectivity and drug resistance, as well as the underlying structural concepts, are discussed in general terms and in the context of relevant kinases and their inhibitors.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Fischer, P. M. (2016). Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview. Medicinal Research Reviews, 37(2), 314–367. https://doi.org/10.1002/med.21409

MLA 9

Fischer, Peter M. “Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview.” Medicinal Research Reviews, vol. 37, no. 2, 2016, pp. 314–367. https://doi.org/10.1002/med.21409.

Chicago

Fischer, Peter M. 2016. “Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview.” Medicinal Research Reviews 37 (2): 314–367. https://doi.org/10.1002/med.21409.

Harvard

Fischer, P. M. (2016) ‘Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview’, Medicinal Research Reviews, 37(2), pp. 314–367. doi:10.1002/med.21409.

IEEE

P. M. Fischer, “Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview,” Medicinal Research Reviews, vol. 37, no. 2, pp. 314–367, 2016, doi: 10.1002/med.21409.

BibTeX

@article{fischer2016approved,
  title     = {{Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview}},
  author    = {Fischer, Peter M.},
  journal   = {Medicinal Research Reviews},
  year      = {2016},
  volume    = {37},
  number    = {2},
  pages     = {314--367},
  doi       = {10.1002/med.21409},
  url       = {https://doi.org/10.1002/med.21409}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
201788
20181313
20191010
202055
20211616
202244
20231212
202477
202555
202633

Its field-weighted citation impact is 1.00: it has been cited 1.00 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy

  • kinase inhibitors
  • small molecule drugs
  • oncology drugs
  • drug approval
  • drug resistance
  • imatinib
  • kinase inhibitor design
  • cancer therapy

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Fischer, P. M. (2016). Approved and Experimental Small‐Molecule Oncology Kinase Inhibitor Drugs: A Mid‐2016 Overview. Medicinal Research Reviews, 37(2), 314–367. https://doi.org/10.1002/med.21409

How many times has this paper been cited?

84 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Repository@Nottingham (University of Nottingham): sign in and open the PDF from this page.

Who wrote this paper?

Peter M. Fischer.

What is the DOI of this paper?

10.1002/med.21409, permanently at https://doi.org/10.1002/med.21409. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.